ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy

被引：0
|
作者：
Jong-Mu Sun
Ji-Youn Sung
Se Hoon Park
Ghee Young Kwon
Byong Chang Jeong
Seong Il Seo
Seong Soo Jeon
Hyun Moo Lee
Jisuk Jo
Han Yong Choi
Ho Yeong Lim
机构：
[1] Sungkyunkwan University School of Medicine,Division of Hematology
[2] Sungkyunkwan University School of Medicine,Oncology, Department of Medicine, Samsung Medical Center
[3] Sungkyunkwan University School of Medicine,Department of Pathology, Samsung Medical Center
[4] Cancer Research Institute,Department of Urology, Samsung Medical Center
[5] Research Institute for Future Medicine,undefined
[6] Samsung Medical Center,undefined
来源：
BMC Cancer | / 12卷
关键词：
Bladder Cancer; Adjuvant Chemotherapy; Transitional Cell Carcinoma; ERCC1 Expression; Nucleotide Excision Repair Pathway;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy
    Bellmunt, J.
    Paz-Ares, L.
    Cuello, M.
    Cecere, F. L.
    Albiol, S.
    Guillem, V.
    Gallardo, E.
    Carles, J.
    Mendez, P.
    de la Cruz, J. J.
    Taron, M.
    Rosell, R.
    Baselga, J.
    ANNALS OF ONCOLOGY, 2007, 18 (03) : 522 - 528
  • [32] ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy
    Klatte, Tobias
    Seitz, Christian
    Rink, Michael
    Roupret, Morgan
    Xylinas, Evanguelos
    Karakiewicz, Pierre
    Susani, Martin
    Shariat, Shahrokh F.
    JOURNAL OF UROLOGY, 2015, 194 (05): : 1456 - 1462
  • [33] Predictive Value of ERCC1, ERCC2, and XRCC1 Overexpression for Stage III Colorectal Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy
    Huang, Ming-Yii
    Tsai, Hsiang-Lin
    Lin, Chih-Hung
    Huang, Ching-Wen
    Ma, Cheng-Jen
    Huang, Chun-Ming
    Chai, Chee-Yin
    Wang, Jaw-Yuan
    JOURNAL OF SURGICAL ONCOLOGY, 2013, 108 (07) : 457 - 464
  • [34] Higher Expression of ERCC1 May Be Associated with Resistance to Adjuvant Platinum-Based Chemotherapy in Gastric Cancer
    Wan, Jiayi
    Chao, Lin
    Lee, Arier C.
    Chen, Qi
    CANCER INVESTIGATION, 2017, 35 (02) : 85 - 91
  • [35] Correlation of ERCC1 expression in peripheral blood lymphocytes with outcomes of patients with gastric cancer treated with oxaliplatin-based adjuvant chemotherapy
    Zhang, Y. Y.
    Gu, K. S.
    Wu, H. Y.
    Yang, F.
    Bu, L. J.
    Zhao, C. C.
    Zhang, Y. R.
    GENETICS AND MOLECULAR RESEARCH, 2015, 14 (04): : 15921 - 15929
  • [36] ERCC1 EXPRESSION AS PREDICTIVE BIOMARKER FOR PLATINUM CONTAINING CHEMOTHERAPY REGIMENS IN OVARIAN CARCINOMA
    Ulker, M.
    Duman, B. B.
    Sahin, B.
    Gumurdulu, D.
    ANNALS OF ONCOLOGY, 2012, 23 : 326 - 326
  • [37] Immunohistochemical staining of the Excision Repair Cross-Complementing 1 (ERCC1) protein as predictor for benefit of adjuvant chemotherapy (CT) in the International Lung Cancer Trial (IALT).
    Soria, J.
    Haddad, V.
    Olaussen, K. A.
    Fouret, P.
    Dunant, A.
    Filipits, M.
    Popper, H. H.
    Andre, F.
    Le Chevalier, T.
    Brambilla, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 366S - 366S
  • [38] ERCC1 in advanced biliary tract cancer patients treated with chemotherapy: Prognostic and predictive roles
    Da Costa Miranda V.
    Braghiroli M.I.
    Faria L.D.B.B.
    Siqueira S.A.C.
    Sabbaga J.
    Hoff P.M.
    Riechelmann R.P.
    Journal of Gastrointestinal Cancer, 2014, 45 (1) : 80 - 86
  • [39] Adjuvant chemotherapy no benefit in patients with rectal cancer
    Pinn, Stephen
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2011, 72 (03) : 130 - 130
  • [40] Correlations between microsatellite instability, ERCC1/XRCC1 polymorphism and clinical characteristics, and FOLFOX adjuvant chemotherapy effect of colorectal cancer patients
    Zhang, Liping
    Zhao, Jiangman
    Yu, Bin
    Song, Xinjiang
    Sun, Guogang
    Han, Lijiang
    Wang, Lu
    Dong, Shu
    CANCER GENETICS, 2017, 218 : 51 - 57
12345